MARKET

AUPH

AUPH

Aurinia Pharmace
NASDAQ
8.00
-0.11
-1.36%
After Hours: 8.07 +0.07 +0.87% 19:51 05/09 EDT
OPEN
8.11
PREV CLOSE
8.11
HIGH
8.21
LOW
7.93
VOLUME
1.51M
TURNOVER
--
52 WEEK HIGH
10.67
52 WEEK LOW
4.990
MARKET CAP
1.09B
P/E (TTM)
203.56
1D
5D
1M
3M
1Y
5Y
1D
Aurinia Pharma Q1 2025 Earnings Preview
Seeking Alpha · 2d ago
Aurinia Pharmaceuticals Inc <AUPH.OQ> expected to post earnings of 10 cents a share - Earnings Preview
Reuters · 2d ago
Uncovering Potential: Aurinia Pharmaceuticals's Earnings Preview
Benzinga · 2d ago
Aurinia Pharmaceuticals to Announce Q1 2025 Results
TipRanks · 6d ago
Weekly Report: what happened at AUPH last week (0428-0502)?
Weekly Report · 6d ago
AURINIA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2025 FINANCIAL AND OPERATIONAL RESULTS ON MAY 12, 2025
Reuters · 6d ago
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
Barchart · 6d ago
Glass Lewis Supports Aurinia’s Proposals for 2025 AGM
TipRanks · 04/30 10:44
More
About AUPH
More
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Recently
Symbol
Price
%Change

Webull offers Aurinia Pharmaceuticals Inc stock information, including NASDAQ: AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.